News Headline Summary

Johnson & Jonhson's (JNJ) Zytiga approved in EU for treatment of Metastatic Castration-resistant Prostate cancer before chemotherapy

Reaction details:

- Co. shares are unmoved in reaction to the news; trades USD 72.45 (+0.36%) last.

Print 15:40, 11 Jan 2013 - US Equities - Source: Newswires